EMEA-002249-PIP01-17

Key facts

Active substance
  • dapagliflozin
  • Saxagliptin
  • metformin (hydrochloride)
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0092/2018
PIP number
EMEA-002249-PIP01-17
Pharmaceutical form(s)
Modified-release tablet
Condition(s) / indication(s)
Treatemnt of type 2 diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB
tel. +46 855327591
E-mail: paediatrics@astrazeneca.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating